	US 12,203,944 B2
	Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement
James Patrick Kampf, San Diego, CA (US); Paul McPherson, Encinitas, CA (US); and Donald Chalfin, Berkeley, CA (US)
Assigned to Astute Medical, Inc., San Diego, CA (US)
Filed by ASTUTE MEDICAL, INC., San Diego, CA (US)
Filed on May 6, 2022, as Appl. No. 17/739,009.
Application 17/739,009 is a continuation of application No. 16/475,326, granted, now 11,353,465, previously published as PCT/US2018/013561, filed on Jan. 12, 2018.
Claims priority of provisional application 62/445,692, filed on Jan. 12, 2017.
Prior Publication US 2023/0025225 A1, Jan. 26, 2023
Int. Cl. G01N 33/68 (2006.01)

CPC G01N 33/6893 (2013.01) [G01N 2333/521 (2013.01); G01N 2800/347 (2013.01); G01N 2800/56 (2013.01)]

21 Claims

1. A method for evaluating renal status in a subject that is diagnosed as having an acute kidney injury (AKI), wherein the subject meets the definition RIFLE I or F or KDIGO Stage 2 or 3, and treating the subject based on the evaluation, the method comprising:

(a) performing an assay configured to detect C-C motif chemokine 14 on a body fluid sample obtained from the subject to provide an assay result indicating a level of C-C motif chemokine 14 in the sample;

(b) determining that the subject is likely to respond favorably to diuretic treatment when the level of C-C motif chemokine 14 in the sample is below a predetermined threshold; and

(c) treating the subject having the level of C-C motif chemokine 14 below the predetermined threshold with diuretic therapy.